Lineage Cell Therapeutics, Inc.

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

Retrieved on: 
월요일, 3월 14, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Optical, Science, Roche, Safety, AMD, Injury, Twitter, Incidence, Adult, Large-cell lung carcinoma, Wills Eye Hospital, Lineage Cell Therapeutics, Company, NYSE American, Research, Thomas Jefferson University, FACS, VAC2, FDA, Cell, CO, ARVO, Visual acuity, Cancer, Colorado Convention Center, Association, RPE, EMA, TASE, Infection, Retinal pigment epithelium, Severe cognitive impairment, Hoffmann-La Roche, Patient, European Medicines Agency, Eye, Vance DeGeneres, Method, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Food, Degenerative disease, Efficacy, Lineage, Pharmaceutical industry, Ophthalmology, Genentech, OpRegen, Dry AMD, Lineage Cell Therapeutics, Inc., OPREGEN, DRY AMD, LINEAGE CELL THERAPEUTICS, INC.

RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.

Key Points: 
  • RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech , a member of the Roche Group.
  • The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC, by a group of 73 ophthalmologists.
  • ARVO is the largest and most respected eye and vision research organization in the world.
  • ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Retrieved on: 
월요일, 12월 20, 2021
Biotechnology, General Health, Pharmaceutical, Health, Therapy, NYSE American, IIA, Infection, Risk, RO, Disease, Injury, Trial of the century, ROG, Forward-looking statement, Lineage, RPE, Retinal pigment epithelium, Visual acuity, Incidence, Interest, U.S. Securities and Exchange Commission, Severe cognitive impairment, Safety, Security (finance), Program, Roche, Webcast, Investor, Cell, Development, Compte rendu, Lineage Cell Therapeutics, Cancer, Degenerative disease, SEC, Medicine, TASE, Vance DeGeneres, Geographic atrophy, Ophthalmology, Large-cell lung carcinoma, Method, Hoffmann-La Roche, Regenerative medicine, AMD, Company, Annual report, VAC2, Patient, Ageing, Technology, Pharmaceutical industry, Genentech, OpRegen, Lineage Cell Therapeutics, Inc., OPREGEN, LINEAGE CELL THERAPEUTICS, INC.

We are excited to partner with Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.

Key Points: 
  • We are excited to partner with Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Retrieved on: 
화요일, 11월 30, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Patient, Security (finance), Visual acuity, Retina, Retinal pigment epithelium, Lineage Cell Therapeutics, Safety, Cell, Annual report, Blood, Forward-looking statement, Company, Surgeon, Large-cell lung carcinoma, Injury, Cancer, NYSE American, Clinical trial, SEC, Human, Severe cognitive impairment, U.S. Securities and Exchange Commission, Vance DeGeneres, Food, Cohort, TASE, Atrophy, Degenerative disease, AMD, OCT, Drusen, Risk, Incidence, Geographic atrophy, FDA, Compte rendu, European Medicines Agency, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RPE, Infection, VAC2, Lineage, Method, Growth, Pharmaceutical industry, Health insurance, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients.

Key Points: 
  • After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients.
  • The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy.
  • We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population.
  • Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression.

OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

Retrieved on: 
월요일, 11월 15, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Genetics, Clinical Trials, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

, Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles.

Key Points: 
  • , Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles.
  • I look forward to our group completing these analyses in the remaining patients as data become available.
  • We are encouraged by this additional supporting evidence obtained from independent analyses of the OpRegen data in patients with atrophic AMD, added Brian M. Culley, Lineage CEO.
  • Restoration of retinal tissue is a compelling finding compared to conventional approaches which to date have only shown an unexceptional slowing of progression.

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

Retrieved on: 
화요일, 10월 26, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, Safety, Bruch, AMD, VAC2, Surgeon, European Medicines Agency, U.S. Securities and Exchange Commission, Compte rendu, OCT, American Academy of Ophthalmology, RPE, Twitter, Gene, Lineage Cell Therapeutics, AAO, Therapy, David Geffen School of Medicine at UCLA, American Academy, Retinal pigment epithelium, History of the University of California, Los Angeles, Incidence, Blood, Severe cognitive impairment, Security (finance), Food, Infection, Injury, Ernest, Annual report, Company, EDT, Degenerative disease, Association, Department, Human embryonic stem cells clinical trials, Large-cell lung carcinoma, SEC, NYSE American, Geographic atrophy, Method, University, Cancer, TASE, FDA, Drusen, Forward-looking statement, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

, Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.

Key Points: 
  • , Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.
  • The American Academy of Ophthalmology is the worlds largest association of eye physicians and surgeons.
  • The mission of the American Academy of Ophthalmology is to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
목요일, 9월 30, 2021
Research, Surgery, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Optical, Science, OCT, Therapy, Geographic atrophy, Bruch, Cohort, Lineage Cell Therapeutics, AMD, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, University, Cell, Safety, VAC2, SEC, Food, Injury, European Medicines Agency, Multimedia, CEI, Infection, NYSE American, Incidence, Association, Retina, Degenerative disease, Severe cognitive impairment, Patient, Annual report, U.S. Securities and Exchange Commission, FDA, Cancer, Method, Company, LLC, Large-cell lung carcinoma, Forward-looking statement, Drusen, Time, Compte rendu, Diagnosis, Retinal pigment epithelium, Security (finance), RPE, Visual acuity, TASE, Trial of the century, NCSS, Blood, Treatment effect, Pharmaceutical industry, Dentistry, Medical imaging, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.

Key Points: 
  • This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.
  • The efficacy findings presented today are both statistically significant as well as clinically important, stated Christopher D. Riemann, M.D.
  • Prior clinical data readouts were mostly descriptive and lacked enough patients and post-treatment follow-up to allow for detailed statistical analyses.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
월요일, 9월 13, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, European Medicines Agency, Drusen, Therapy, Association, Food, Incidence, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lineage Cell Therapeutics, Injury, University, Degenerative disease, VAC2, Clinical trial, Retina, TASE, Patient, Infection, Company, Retinal pigment epithelium, NYSE American, Bruch, Spinal cord injury, CEI, Severe cognitive impairment, Safety, Large-cell lung carcinoma, Blood, The Ritz-Carlton Hotel Company, Diagnosis, Cancer, AMD, Geographic atrophy, Method, RPE, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.

Key Points: 
  • The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.
  • The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA).

OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

Retrieved on: 
화요일, 7월 20, 2021
Biotechnology, Optical, Health, Clinical trials, Ophthalmology, Organ systems, Vision, Geographic atrophy, Macular degeneration, Blindness, Retinal pigment epithelium, Retina, Emerging technologies, Diabetic retinopathy, Retinopathy, Gene therapy of the human retina, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells, administered one time to the subretinal space, for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).

Key Points: 
  • OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells, administered one time to the subretinal space, for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
  • We look forward to continuing to follow all study patients and reporting our efficacy and safety observations over time.
  • Improvements in best corrected visual acuity (BCVA) for Cohort 4 patients reached up to +19 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.
  • There are two forms of AMD: dry (atrophic) AMD and wet (neovascular) AMD.

OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
화요일, 7월 13, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Vision, Sensory systems, Nervous system, Optometry, Visual system, Retina, Visual acuity, Visual perception, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.

Key Points: 
  • The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.
  • The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA).

Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes

Retrieved on: 
월요일, 6월 28, 2021
Medical devices, Hospitals, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Stock market indices, FTSE Russell, London Stock Exchange, Russell Microcap Index, Russell Indexes, Financial markets, Finance, Index, Lineage Cell Therapeutics, Tel Aviv Stock Exchange, Microcap stock, Russell 2500 Index, FTSE Russell, Lineage Cell Therapeutics, Inc., FTSE RUSSELL, LINEAGE CELL THERAPEUTICS, INC.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both the broad-market Russell 3000 Index as well as the Russell Microcap Index.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both the broad-market Russell 3000 Index as well as the Russell Microcap Index.
  • Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
  • The information in this announcement about the Russell indexes and FTSE Russell was obtained from FTSE Russell.